| CAS NO: | 660-88-8 |
| 包装 | 价格(元) |
| 5g | 电议 |
| 25g | 电议 |
| Cas No. | 660-88-8 |
| 别名 | 5-氨基戊酸 |
| 化学名 | 5-aminopentanoic acid |
| Canonical SMILES | O=C(O)CCCCN |
| 分子式 | C5H11NO2 |
| 分子量 | 117.15 |
| 溶解度 | Soluble in DMSO |
| 储存条件 | Store at -20°C |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
| 产品描述 | 5-Aminovaleric acid has been identified as an important five-carbon platform chemical, which can be used for the synthesis of polymers and other chemicals of industrial interest as well. In vitro: 5-Aminovaleric acid, a GABA analog, was reported to be able to inhibit GABA uptake, inactivate GABA aminotransferase, and could also both agonize and antagonize GABAb receptors. In addition, 5-aminovaleric acid has been found to be able to increase glutamine concentrations, thus possibly compensating for the decreased concentration of brain glutamine [1]. In vivo: Animal study found that 5-aminovaleric acid-treated rats showed a 3.5-fold reduction in the number of seizures than PBS-treated rats. In addition, both groups showed similar seizure frequency (~1 seizure/day). However, the fraction of the most severe type of seizures increased over time in the PBS treated group, but not in the 5-aminovaleric acid treated group. Moreover, 5-aminovaleric acid treated rats experienced a 2.3- and 2.6-fold lower fraction of stage 4 and 5 seizures than PBS-treated rats [1]. Clinical trial: Aminocaproic acid has been approved by FDA for the treatment of acute bleeding caused by elevated fibrinolytic activity. It has also been used for the prevention of recurrent hemorrhage in patients with traumatic hyphema [https://en.wikipedia.org/wiki/Aminocaproic_acid]. Reference: |
m.cnreagent.com